Quarterly report [Sections 13 or 15(d)]

REVENUES (Tables)

v3.25.2
REVENUES (Tables)
6 Months Ended
Jun. 30, 2025
REVENUES  
Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):

Three Months Ended June 30, 

Six Months Ended June 30, 

2025

    

2024

2025

    

2024

Product sales:

Gross product sales

$

79,692

$

48,980

$

139,884

$

87,406

Discounts and allowances

(20,744)

(15,530)

(37,386)

(27,953)

Total product sales, net

58,948

33,450

102,498

59,453

Revenues from collaborations:

Release of cost share liability

39,981

39,981

Milestone revenue

3,000

Delivery of drug supplies, royalty and others

2,756

3,391

9,539

6,922

Total revenues from collaborations

42,737

3,391

52,520

6,922

Total revenues

$

101,685

$

36,841

$

155,018

$

66,375

Schedule of product revenue allowance and reserve categories

The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance as of January 1, 2025

    

$

13,374

$

8,343

$

4,723

$

26,440

Provision related to current period sales

28,209

8,082

923

37,214

Adjustment related to prior period sales

(169)

(560)

(729)

Credit or payments made during the period

(28,624)

(4,642)

(157)

(33,423)

Balance as of June 30, 2025

 

$

12,959

$

11,614

$

4,929

$

29,502

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance as of January 1, 2024

    

$

8,236

$

3,517

$

3,931

$

15,684

Provision related to current period sales

21,770

5,259

522

27,551

Credit or payments made during the period

(20,165)

(4,441)

(82)

(24,688)

Balance as of June 30, 2024

 

$

9,841

$

4,335

$

4,371

$

18,547

Schedule of revenues from product sales disaggregated by customers

Three Months Ended June 30, 

Six Months Ended June 30, 

2025

    

2024

2025

    

2024

McKesson Corporation

31%

49%

35%

46%

Cencora, Inc.

12%

20%

15%

21%

Cardinal Health, Inc.

*

21%

*

22%

Lilly

39%

26%